Results 71 to 80 of about 2,846 (197)

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Supplementary Figure 2 from The Integrin Inhibitor Cilengitide Affects Meningioma Cell Motility and Invasion

, 2013
Supplementary Figure 2 - PDF file 128K, Cell cycle analyses under cilengitide treatment.
Jan-Peter Warnke (11091068), Peter Hass (659595), Annette Wilisch-Neumann (14988846), Werner EK Braunsdorf (14988855), Christian Mawrin (2102), Thomas Schneider (252444), Elmar Kirches (8669856), Doreen Pachow (14988852), Cornelia Helbing (14988861), Diana Pasemann (14988858), Nadine Kliese (14988849), Frank-Dietmar Böhmer (478219)   +11 more
core   +1 more source

Inhibition of TGFβ1 activation prevents radiation‐induced lung fibrosis

Clinical and Translational Medicine
Background Radiotherapy is the main treatment modality for thoracic tumours, but it may induce pulmonary fibrosis. Currently, the pathogenesis of radiation‐induced pulmonary fibrosis (RIPF) is unclear, and effective treatments are lacking.
Minxiao Yi, Ye Yuan, Li Ma, Long Li, Wan Qin, Bili Wu, Bolong Zheng, Xin Liao, Guangyuan Hu, Bo Liu   +9 more
doaj   +1 more source

The Role of αvβ3 Integrin in Lamina Cribrosa Cell Mechanotransduction in Glaucoma

Cells
Purpose: Glaucoma, one of the leading causes of irreversible blindness, is a common progressive optic neuropathy characterised by visual field defects and structural changes to the optic nerve head (ONH).
Mustapha Irnaten, Ellen Gaynor, Colm O’Brien   +2 more
doaj   +1 more source

L1CAM Promotes the Infiltrative Properties of Patient‐Derived Glioblastoma Cells

Cancer Science, Volume 117, Issue 5, Page 1380-1396, May 2026.
In vivo validation of L1CAM‐mediated GBM infiltration. Orthotopic transplantation of L1CAM‐expressing GBM cells into mouse brains demonstrated that L1CAM significantly promotes tumor cell infiltration and expansion in the brain parenchyma, confirming its critical role in the aggressive progression of GBM.
Asako Katsuma, Daisuke Kanematsu, Yukako Handa, Tomoko Shofuda, Atsuyo Yamamoto, Kayo Nishitani, Zhize Xiao, Daisuke Kawauchi, Kentarou Baba, Naoyuki Inagaki, Yonehiro Kanemura   +10 more
wiley   +1 more source

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

, 2008
BACKGROUND: Glioblastoma multiforme (GBM), a highly invasive and vascular cancer, responds poorly to conventional cytotoxic therapy. Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis.
Mikkelsen, T., Reardon, D.A., Stupp, R., Nabors, L.B.   +3 more
core   +1 more source

Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis

Current Oncology
Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression.
Célia Gotorbe, Fabien Segui, William Echavidre, Jérôme Durivault, Thays Blanchard, Valérie Vial, Marina Pagnuzzi-Boncompagni, Rémy Villeneuve, Régis Amblard, Nicolas Garnier, Cécile Ortholan, Benjamin Serrano, Vincent Picco, Jacques Pouysségur, Milica Vucetic, Christopher Montemagno   +15 more
doaj   +1 more source

Cilengitide Treatment for Malignant Glioma: Current Status and Future Direction

Neurologia medico-chirurgica, 2012
Malignant glioma is the most common primary brain tumor and accounts for the majority of diagnoses. Treatment has involved a combination of surgery, radiation, and chemotherapy, yet these modalities rarely extend the life of the patient to more than one year from diagnosis.
KUROZUMI, Kazuhiko, ICHIKAWA, Tomotsugu, ONISHI, Manabu, FUJII, Kentaro, DATE, Isao   +4 more
openaire   +3 more sources

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma [PDF]

Neuro-Oncology, 2015
Despite being a highly vascularized tumor, glioblastoma response to anti-vascular endothelial growth factor (VEGF) therapy is transient, possibly because of tumor co-option of preexisting blood vessels and infiltration into surrounding brain. Integrins, which are upregulated after VEGF inhibition, may play a critical role in this resistance mechanism ...
Elizabeth R, Gerstner, Xiaobu, Ye, Dan G, Duda, Michael A, Levine, Tom, Mikkelsen, Thomas J, Kaley, Jeffrey J, Olson, Burt L, Nabors, Manmeet S, Ahluwalia, Patrick Y, Wen, Rakesh K, Jain, Tracy T, Batchelor, Stuart, Grossman   +12 more
openaire   +2 more sources

Biodegradable Carbonate Nanogels Loaded with Anti MFAP‐5 siRNA for Anti‐stromal Therapy of Hepatocellular Carcinoma

Advanced Science, Volume 13, Issue 21, 13 April 2026.
Polycarbonate nanogels enable lipid‐free delivery of anti‐MFAP‐5 siRNA into cancer‐associated fibroblasts (CAF) in hepatocellular carcinoma. In a cirrhotic murine model, this approach silences MFAP‐5, reduces fibroblast activation, and suppresses tumor growth by inhibiting NOTCH/Hes1‐driven angiogenesis. CAF‐targeted MFAP‐5 RNAi and conserved signaling
Paul Schneider, Alexander Fuchs, Michael Fichter, Vanessa Bolduan, Jenny Schunke, Özlem Akilli, Nádia C. Correia, Yannick Ehlers, Christian Czysch, Pia Winterwerber, Eliana Stanganello, Barbara Schrörs, Mustafa Diken, Christoph Eckert, Shusruto Rishik, Andreas Keller, Jörn M. Schattenberg, Stephan Grabbe, Matthias Bros, Lutz Nuhn, Leonard Kaps   +20 more
wiley   +1 more source